articleJournal of Clinical OncologyFeb 17, 2022BRONZE OA

Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion

DCDebyani ChakravartyAJAmber JohnsonJSJeffrey SklarNINeal I. LindemanKMKathleen Moore

Memorial Sloan Kettering Cancer Center · The University of Texas MD Anderson Cancer Center · +17 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

PURPOSE An ASCO provisional clinical opinion offers timely clinical direction to ASCO's membership following publication or presentation of potentially practice-changing data from major studies. This provisional clinical opinion addresses the appropriate use of tumor genomic testing in patients with metastatic or advanced solid tumors. CLINICAL CONTEXT An increasing number of therapies are approved to treat cancers harboring specific genomic biomarkers. However, there is a lack of clarity as to when tumor genomic sequencing should be ordered, what type of assays should be performed, and how to interpret the results for treatment selection. PROVISIONAL CLINICAL OPINION Patients with metastatic or advanced…

Citation impact

241
total citations
FWCI
20.03
Percentile
100%
References
194
Citations per year

Authors

18
  • DC
    Debyani ChakravartyCorresponding

    Memorial Sloan Kettering Cancer Center

  • AJ
    Amber Johnson

    The University of Texas MD Anderson Cancer Center

  • JS
    Jeffrey Sklar

    Yale University

  • NI
    Neal I. Lindeman

    Brigham and Women's Hospital, Harvard University

  • KM
    Kathleen Moore

    Oklahoma State University Oklahoma City, OU Health Stephenson Cancer Center

Topics & keywords

Topics
Keywords
  • Targeted therapy
  • Clinical trial
  • Cancer
  • Personalized medicine
  • Precision medicine
  • Somatic cell
  • Genetic testing
  • Mutation
No related works found for this paper.

Funding